Why is Biogen Pharma falling/rising?

As of 05-Sep, Biogen Pharmachem Industries Ltd is experiencing a decline in its stock price, currently at 0.89, reflecting a decrease of 0.01 or 1.11%. The stock has underperformed its sector by 1.64% today and has been on a downward trend, falling for the last two consecutive days with a total decline of 2.2%. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Despite declaring positive results for the last two quarters, including significant growth in profit before tax and profit after tax, the company's long-term fundamental strength is weak, indicated by a low return on equity of 2.43% and a poor EBIT to interest ratio of 1.19. This combination of factors suggests that while there are some positive short-term results, the overall outlook remains concerning, contributing to the stock's recent decline.
In the broader market context, Biogen's performance over the past week shows a decline of 1.11%, while the benchmark Sensex has increased by 1.13%. Over the past month, Biogen's stock has decreased by 4.30%, contrasting with the Sensex, which remained flat. Year-to-date, Biogen has seen a significant drop of 24.58%, while the Sensex has gained 3.29%. This stark difference highlights the stock's struggles relative to the broader market, reinforcing the perception of its weak performance and investor sentiment.